Neoral (Ciclosporin)

Ciclosporin, the active ingredient in Neoral, is a calcineurin inhibitor presented as an oral solution for oral administration. It suppresses the immune response by inhibiting T‑lymphocyte activation and is primarily employed to prevent rejection of transplanted organs in adult and pediatric patients under specialist care. The formulation is approved in the European Union and requires prescription by a qualified healthcare professional.

GNH USA supplies Neoral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Neoral (cyclosporin) is an immunosuppressant that acts on the calcineurin pathway to prevent organ rejection. - Kidney transplantation: reduces the risk of acute and chronic graft rejection. - Liver transplantation: maintains graft function by suppressing immune‑mediated injury. - Heart transplantation: helps prevent immune‑mediated rejection episodes. - Bone marrow transplantation: used as part of prophylaxis against graft‑versus‑host disease.

Neoral may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tremor: fine shaking of hands or limbs. - Hypertension: elevated blood pressure. - Hyperlipidaemia: increased cholesterol or triglyceride levels. - Gingival hyperplasia: overgrowth of gum tissue.

Serious or Rare Side Effects: - Nephrotoxicity: significant kidney injury requiring medical attention. - Severe infections: opportunistic infections due to immunosuppression. - Malignancy: increased risk of lymphoma or skin cancers.

When prescribing Neoral, clinicians should consider several precautionary measures to minimise risk. - Baseline renal function: assess serum creatinine and glomerular filtration rate before initiation. - Blood pressure monitoring: check regularly due to risk of hypertension. - Lipid profile: monitor cholesterol and triglycerides during therapy. - Drug interactions: review concomitant medications that affect cytochrome P450 enzymes. - Infection risk: evaluate for active infections and vaccinate appropriately before starting. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Neoral interacts with several medicines that can alter its concentration or enhance toxicity.

Major Interactions (Avoid): - Ketoconazole, itraconazole, or other strong CYP3A4 inhibitors: may markedly increase cyclosporin levels, risking nephrotoxicity. - Rifampicin or other potent CYP3A4 inducers: can reduce cyclosporin exposure, leading to graft rejection. - NSAIDs (e.g., ibuprofen, diclofenac): increase risk of renal impairment when combined.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., diltiazem, verapamil): may raise cyclosporin concentrations; monitor levels. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): can elevate cyclosporin; adjust dose as needed. - Antifungal agents (e.g., fluconazole): may increase cyclosporin exposure; periodic monitoring recommended.